Cargando…
Syk inhibitors in clinical development for hematological malignancies
Spleen tyrosine kinase (Syk) is a cytosolic non-receptor protein tyrosine kinase (PTK) and is mainly expressed in hematopoietic cells. Syk was recognized as a critical element in the B-cell receptor signaling pathway. Syk is also a key component in signal transduction from other immune receptors lik...
Autores principales: | Liu, Delong, Mamorska-Dyga, Aleksandra |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5534090/ https://www.ncbi.nlm.nih.gov/pubmed/28754125 http://dx.doi.org/10.1186/s13045-017-0512-1 |
Ejemplares similares
-
Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia
por: Seiter, Karen, et al.
Publicado: (2015) -
Autoimmune hemolytic anemia associated with babesiosis
por: Narurkar, Roshni, et al.
Publicado: (2017) -
Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application
por: Furqan, Muhammad, et al.
Publicado: (2013) -
Selective inhibitors of nuclear export (SINE) in hematological malignancies
por: Das, Arundhati, et al.
Publicado: (2015) -
Checkpoint inhibitors in hematological malignancies
por: Ok, Chi Young, et al.
Publicado: (2017)